Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.
Luke Nordquist, MD
Advertisement
Articles by Luke Nordquist, MD
Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
Advertisement
Latest Updated Articles
Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPCPublished: September 17th 2016 | Updated:
- Dr. Luke Nordquist on Who Should Receive Radium-223
Published: October 21st 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5